Monday, December 23

New Delhi: In Ayushman Bharat-Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) of the Ministry of Health & Family Welfare (Mohfw) in the category of authorised hospital admissions Southern states are leading as four toppers namely Tamil Nadu, Karnataka, Kerala and Andhra Pradesh are among the first five in the category.

The breakup of the authorised hospital admissions since the scheme’s inception is topped by Tamil Nadu with 9.05 million hospital admissions, followed by Karnataka (6.60 million), Rajasthan (5.74 million), Kerala (5.46 million) and Andhra Pradesh (4.96 million), according to data available on the PMJAY dashboard.This southern dominance comes at a time when none of these states figure in the top five in creating Ayushman cards. Karnataka (17.5 million cards) and Andhra Pradesh (15.6 million cards) are the highest card creating states in the south, placed eighth and tenth on the list. Telangana, which joined the scheme only in 2021, has 8.29 million Ayushman cards, which is more than Kerala (7.70 million cards) and Tamil Nadu (7.54 million cards). However, besides Tamil Nadu and Kerala, other southern states have witnessed a growth in hospital admissions under the scheme since the last three financial years, according to data presented by the Ministry of Health and Family Welfare in the parliament. Hospital admissions under the scheme in Tamil Nadu hospitals have come down from 4.39 million in financial year 2022 (FY22) to 1.05 million in FY24.

Share.
Leave A Reply

Doctor Post is a health news portal tailored to provide updates for medical and healthcare professionals, while remaining open to others interested in accessing general health information. The content on Doctor Post is carefully created and/or edited by a dedicated team of doctors, healthcare researchers, and scientific writers.

© 2024 Doctor Post. All Rights Reserved. Created and Maintained by Creative web Solution

Disclaimer: Use of the site is governed by our terms of use, privacy policy, and advertisement policy. For further details, please refer to our Disclaimer.

Exit mobile version